These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29674502)

  • 21. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Expert Rev Hematol; 2019 Jun; 12(6):383-395. PubMed ID: 31107120
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Bonnez Q; Sakai K; Vanhoorelbeke K
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.
    Mazepa MA; Masias C; Chaturvedi S
    Blood; 2019 Aug; 134(5):415-420. PubMed ID: 31217190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
    Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
    Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current concepts in thrombotic thrombocytopenic purpura.
    Tsai HM
    Annu Rev Med; 2006; 57():419-36. PubMed ID: 16409158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity.
    Tellier E; Widemann A; Cauchois R; Faccini J; Lagarde M; Brun M; Robert P; Robert S; Bachelier R; Poullin P; Roose E; Vanhoorelbeke K; Coppo P; Dignat-George F; Kaplanski G
    Haematologica; 2023 Apr; 108(4):1127-1140. PubMed ID: 36453103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelets: thrombotic thrombocytopenic purpura.
    George JN; Sadler JE; Lämmle B
    Hematology Am Soc Hematol Educ Program; 2002; ():315-34. PubMed ID: 12446430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.
    Mancini I; Ricaño-Ponce I; Pappalardo E; Cairo A; Gorski MM; Casoli G; Ferrari B; Alberti M; Mikovic D; Noris M; Wijmenga C; Peyvandi F;
    J Thromb Haemost; 2016 Dec; 14(12):2356-2367. PubMed ID: 27762046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura.
    Picod A; Coppo P
    Expert Rev Hematol; 2019 Jun; 12(6):461-471. PubMed ID: 31092093
    [No Abstract]   [Full Text] [Related]  

  • 34. Current management of thrombotic thrombocytopenic purpura.
    Kremer Hovinga JA; Meyer SC
    Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.
    Schelpe AS; Roose E; Joly BS; Pareyn I; Mancini I; Biganzoli M; Deckmyn H; Voorberg J; Fijnheer R; Peyvandi F; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
    Haematologica; 2019 Jun; 104(6):1268-1276. PubMed ID: 30523052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults.
    Blennerhassett R; Curnow J; Pasalic L
    Semin Thromb Hemost; 2020 Apr; 46(3):289-301. PubMed ID: 32259874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombotic thrombocytopenic purpura: a moving target.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired TTP: ADAMTS13 meets the immune system.
    Verbij FC; Fijnheer R; Voorberg J; Sorvillo N
    Blood Rev; 2014 Nov; 28(6):227-34. PubMed ID: 25213289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.